Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2023 Feb 23;14:1163550. doi: 10.3389/fimmu.2023.1163550

Corrigendum: The Vacc-SeqQC project: Benchmarking RNA-Seq for clinical vaccine studies

Johannes B Goll 1,, Steven E Bosinger 2,3,4,5,, Travis L Jensen 1, Hasse Walum 2, Tyler Grimes 1, Gregory K Tharp 4, Muktha S Natrajan 5,6, Azra Blazevic 7, Richard D Head 8, Casey E Gelber 1, Kristen J Steenbergen 1, Nirav B Patel 4, Patrick Sanz 9, Nadine G Rouphael 5,6,10, Evan J Anderson 10,11, Mark J Mulligan 5,6,10,12,*,, Daniel F Hoft 7,13,*,
PMCID: PMC9996330  PMID: 36911714

In the published article, there was an error in the Figure 7 legend as published. The figure legend effect size values were incorrectly displayed as “>1.25, 51.5, 51.75, 52” instead of “>1.25, ≥1.5, ≥1.75, ≥2”. The corrected Figure 7 and its caption appear below.

Figure 7.

Figure 7

Relative power by sample size, effect size, and sequencing depth at each post-vaccination day as simulated using the modified PROPER R package. Days were sorted by decreasing vaccination effect based on overall fold changes and DEG responses observed for this study (see Figure 3A). Power was assessed for different fold-change cutoffs (indicated by color-coded lines), sequencing depth (as indicated by the line type), and sample size (x-axis).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES